SION - Sionna Therapeutics, Inc. Common Stock

https://www.sionnatx.com

Hold Momentum: Bearish

Recent News

All You Need to Know About Sionna Therapeutics, Inc. ( SION ) Rating Upgrade to Buy

Zacks Commentary • 0 minutes ago • score: 0.36

Sionna Therapeutics, Inc. (SION) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bullish

Sionna Therapeutics to Participate in Upcoming September Investor Conferences - Sionna Therapeutics ( NASDAQ:SION )

Benzinga • 2 weeks, 5 days ago • score: 0.25

WALTHAM, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Sionna Therapeutics, Inc.

Bullish

Sionna Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.20

WALTHAM, Mass., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Sionna Therapeutics, Inc. ( Nasdaq: SION ) , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis ( CF ) by developing novel medicines that normalize the function of the ...

Bullish

Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis

GlobeNewswire • 3 weeks ago • score: 0.28

Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers. topline data anticipated in mid-2026 Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers. topline data anticipated in ...

Neutral

Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday - Critical Metals ( NASDAQ:CRML ) , Blue Gold ( NASDAQ:BGL )

Benzinga • 2 months, 1 week ago

U.S. stocks were mixed, with the Dow Jones index falling over 100 points on Wednesday. Shares of Hut 8 Corp. HUT rose sharply during Wednesday's session after announcing a key infrastructure win in Ontario.

Bullish

Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model

GlobeNewswire • 3 months, 1 week ago • score: 0.33

Data featured in oral presentation and poster session at 48th European Cystic Fibrosis Conference ...

Bullish

Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Sionna Therapeutics ( NASDAQ:SION )

Benzinga • 3 months, 1 week ago • score: 0.28

SION-719 and SION-451 hit PK targets with no serious adverse events across 210 healthy volunteers. Sionna plans Phase 2a for SION-719 and a dual combo trial for SION-451 starting in 2H 2025. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.

Bullish

Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - Sionna Therapeutics ( NASDAQ:SION )

Benzinga • 3 months, 1 week ago • score: 0.24

WALTHAM, Mass., June 03, 2025 ( GLOBE NEWSWIRE ) -- Sionna Therapeutics, Inc.

Bullish

Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference

GlobeNewswire • 3 months, 3 weeks ago • score: 0.32

WALTHAM, Mass., May 22, 2025 ( GLOBE NEWSWIRE ) -- Sionna Therapeutics, Inc. ( Nasdaq: SION ) , a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis ( CF ) by developing novel medicines that normalize the function of the ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

None

52W High

$26.50

52W Low

$7.25

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

2.10

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

7.20%

Institutions (25–75% balanced)

93.43%

Shares Outstanding

44,092,100

Float

11,223,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

As of 2025-03-31 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-1.50

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

N/A

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

0.9216

1.0970

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025